Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis)

Published
05 December 2012
By
Liz Highleyman
Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising

The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012,

Published
05 December 2012
By
Liz Highleyman
Monoclonal antibody GS-6624 well tolerated by patients with hepatic fibrosis in initial safety study

Patients with hepatic fibrosis treated with monoclonal antibody GS-6624 experienced reductions to AST and ALT levels with no serious adverse events, treatment discontinuations or dose adjustments in a study presented at The Liver Meeting.

Published
04 December 2012
From
Healio Hepatology
Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon

An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C

Published
03 December 2012
By
Liz Highleyman
Medical Technician Accused in Hepatitis C Infections Is Indicted on New Charges

A traveling medical technician who is believed to have infected at least 39 people with hepatitis C through his use of stolen hospital drugs and syringes was indicted late Wednesday in New Hampshire on 14 new charges.

Published
03 December 2012
From
New York Times
Nucleoside analogues reduce hepatitis B liver cancer risk

Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection

Published
29 November 2012
By
Liz Highleyman
European Commission approves Viread ® for HIV-1 infection in children and adolescents and for chronic hepatitis B in adolescents

New oral granule formulation and lower-strength tablets available for new indications.

Published
28 November 2012
From
Gilead press release
Copy of European Commission approves Viread ® for HIV-1 infection in children and adolescents and for chronic hepatitis B in adolescents

New oral granule formulation and lower-strength tablets available for new indications.

Published
28 November 2012
From
Gilead press release
Hepatitis C Reaching Crisis Levels; Requires Coverage for Routine Screenings

As the countdown to implementation of the Affordable Care Act begins in earnest, experts on the front lines in fighting viral hepatitis and HIV/AIDS issued this harsh assessment regarding escalating levels of hepatitis C virus (HCV) infection: unless policymakers require insurers to cover the costs of screening everyone at potential risk for HCV, rates of cirrhosis and liver cancer will continue to rise and become a major drain on the healthcare system.

Published
28 November 2012
From
National Summit on HIV and Viral Hepatitis press release
Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

POSITRON Demonstrates Efficacy of a 12-Week All-Oral Regimen of Sofosbuvir Plus Ribavirin for Chronic Hepatitis C Patients who are Unable or Unwilling to Take Interferon

Published
27 November 2012
From
Gilead press release

Filter by country